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Objectives. The characteristic features of Mikulicz’s disease (MD) are diﬀuse enlargement of the lacrimal and submandibular
glands, elevated levels of serum immunoglobulin (Ig)G4, and abundant inﬁltration of IgG4-positive plasmacytes into both glands.
No disease index is available to properly evaluate MD, so we developed a functional assessment of MD, the Mikulicz’s disease
activityquestionnaire(MAQ),andevaluated itsclinicaleﬃcacy. Methods.Weselected18patientswhowereeitherbeingtreatedfor
MD or who had presented with recurrence. The patients completed a self-assessment and were scored according to the MAQ sheet
during each visit between December 2009 and August 2011. Assessment items were in regard to increases or decreases in lacrimal
and salivary gland enlargement and severity of sicca symptoms. Results. On the ﬁrst visits, MAQ scores were high, but scores
decreased rapidly as treatment progressed. When doses of glucocorticoid were reduced, some patients showed increased scores.
Dry-symptom scores increased initially. MAQ scores for patients with recurrent MD gradually increased over several months
before relapse. However, some patients displayed no elevation in MAQ scores due to relapses at other sites. Conclusion.M A Qs c o r e
can be used to quantify ﬂares and treatment response and is useful for functional assessment of MD.
1.BackgroundandPurpose
Mikulicz’s disease (MD) is a chronic inﬂammatory disease
characterizedby diﬀuseenlargementofthelacrimalandsub-
mandibular glands, elevated levels of serum immunoglob-
ulin (Ig)G4, and abundant inﬁltration of IgG4-positive
plasmacytes and ﬁbrosis in both glands. MD is considered as
an IgG4-related disease (IgG4-RD) with aspects of systemic
disorders [1]. Several epidemiological studies have shown
that thousands of patients in Japan have MD [2]. The
pathogenesis of IgG4-RD involves a gradual shift from an
inﬂammatory stage to a ﬁbrotic stage. Early intervention
with appropriate therapy is necessary to avoid irreversible
organ dysfunction. One of the features of MD is a high
relapse rate following reductions in glucocorticoid treat-
ment, as this steroid is known to be useful in achieving
clinical remission [3].
As a representative chronic disorder, treatment of
rheumatoidarthritis(RA)requirespreciseclinicalevaluation
and review of the course of treatment [4]. Similar principles
would apply to MD, but no clinical index has been available
to properly evaluate this pathology. The health assessment
questionnaire (HAQ) was developed as a comprehensive
measure of outcomes in patients with a wide variety of
rheumatic diseases [5], but does not reﬂect the condition
of MD particularly well because MD is a local condition
aﬀecting only the lacrimal and salivary glands. A system
for assessing disease activity and functional impairment
in patients with MD is thus needed, and we therefore
developed a functional evaluation system, the “Mikulicz’s
disease activity questionnaire” (MAQ), and have applied
this in daily practice since December 2009. The present
study analyzed the clinical eﬃcacy of MAQ in patients with
MD.2 International Journal of Rheumatology
2. Methods
We conducted a followup study of 18 MD patients from
December 2009 to August 2011. Diagnoses were made ac-
cording to the diagnostic criteria for IgG4-related MD pro-
posedbytheJapaneseSociety forSj¨ ogren’s syndrome in 2008
(Figure 4)[ 6] and by the pathological evaluation of enlarged
submandibular glands. Study subjects included patients who
had started treatment and patients who presented with
relapses. Patients under 20 years old were excluded. At
the hospital and related institutes, patients assessed the
severity of their own lacrimal and salivary gland swelling and
recorded the scores on the MAQ. Levels of serum IgG4 were
also measured continuously. We analyzed the serial changes
in MAQ score with treatment.
The MAQ score sheet (Figure 1) comprises four ques-
tions to assess the degrees to which the lacrimal and salivary
glands were enlarged and the occurrence and severity of
sicca symptoms. Patients checked the boxes that best corre-
sponded to current symptoms: disappearance of symptoms
(0 points); slight improvement of symptoms (1 point);
unchanged symptoms (2 points); worsening of symptoms
(3 points). MAQ scores were determined as the total of the
swelling-evaluation points and dryness-evaluation points,
allowing us to compare the conditions of patients compared
withtheﬁrstvisit.Wealsorecordedtheamountofprescribed
glucocorticoid at each visit. No patients were given any
guidance including leading questions in this assessment. If
marked diﬀerences were seen in assessment results between
patients and doctors, we asked the doctors to record
comments in the MAQ sheets. In MD, relapse was deﬁned as
reenlargement of the lacrimal and salivary glands on physical
and image ﬁndings. In other organs, MD relapse was deﬁned
as swelling of organs on systemic enhanced CT examined
periodically. However, for renal lesions, we considered the
appearance of contrast defects in the renal parenchyma as
indicative of ﬂare-up.
Treatment was performed as follows. For patients with
failure of organs other than the lacrimal and salivary glands,
we initially prescribed 0.8mg/kg/day of prednisolone (PSL)
for 1 month and then reduced the amount by 10% every 2
weeks. For those patients without organ failure, we initially
prescribed 0.6mg/kg/day of PSL [6]. After the dose was
decreased to <10mg/day, we continued to administer a
maintenance dose for 6 months. After 6 months, the doctors
reduced the amount of steroid if the patient was in clinical
remission. If a relapse occurred, the dose of glucocorticoid
was increased. In our analysis, clinical remission was deﬁned
as no observation of lacrimal or salivary gland enlargement
over a 3-month period as determined by physical and
imaging ﬁndings. Recurrence was deﬁned as the necessity
for treatment intervention due to swelling of the glands or
detection of other organ dysfunction.
3. Results
3.1. Patient Proﬁles. The 41 participants in the followup
study comprised 17 men and 24 women. Mean (±standard
deviation) age at MD onset was 56.59 ± 11.90 years, and
meanageatdiagnosiswas58.44±11.52years.Meanduration
of followup from the ﬁrst visit was 4.00 ± 2.36 years. Seven
patients (17.1%) started treatment with glucocorticoid, and
11 patients (26.8%) presented with recurrence during the
observation period. As of December 2009, 23 cases had been
prescribed with steroid and showed no ﬂare-up during the
study period (Table 1).
3.2. Analysis of Patients Starting Treatment. The 7 patients
who began treatment during the observation period showed
high MAQ scores of 8.3±1.7 at the ﬁrst visit. Starting steroid
doses were as follows: 40mg/day in 1 patient; 30mg/day
in 5 patients; 25mg/day in 1 patient. Doctors continued to
prescribePSLat4to7mg/dayatlastvisit.Asallpatientspro-
gressedwithtreatment,MAQscoresincludingdrynessscores
rapidlydecreased;scoreswere<1inallcaseswhenthedoseof
PSL was reduced to 20mg/day. Some cases initially presented
with sicca symptoms and subsequently showed an increase
in questionnaire scores at 8 to 10mg/day (Figure 2(a)).
In untreated patients, however, mean serum level of IgG4
was 368.71 ± 162.28mg/dL. Patient levels of IgG4 also
decreased after the initiation of treatment, but at <15mg/day
of PSL, IgG4 levels in some patients reelevated in advance
of reelevations in MAQ scores. Almost all patients showed
an elevation of serum IgG4 at the dose point of 5mg/day
(Figure 2(b)). In this study, no cases were seen in which
assessments diﬀered markedly between patients and doctors.
3.3. Analysis of Patients Presenting with Relapse. Among the
11 patients who presented with relapses during observation,
2 experienced more than one relapse. The steroid dose for
these patients at the time of relapse was 0 to 16mg/day, and
the mean dose was 6.86±4.54mg/day. Most of these patients
received an additional amount of steroid, but patients with
repeated past recurrences received immunosuppressants
such as mizoribine or rituximab. Mean MAQ scores at ﬁrst
relapse were 2.7 ± 2.1, with scores of 0 in two cases. Many
cases showed a gradual elevation in MAQ scores at 1 to 6
months before relapse (Figure 3(a)). This tendency toward
elevation was marked in dryness scores. In two patients who
presented with more than one relapse, MAQ scores showed
an unstable transition after the PSL dose was increased.
We also found that these patients showed elevated levels
of serum IgG4 several months before relapse (Figure 3(b)).
LevelsofserumIgG4decreasedimmediatelyafteranincrease
in steroid dose, but reelevation of serum IgG4 was observed
with a reduction of glucocorticoid (data not shown). As
with patients starting treatment, no cases showed marked
diﬀerences in assessments between patients and doctors.
4. Discussions
MD is a chronic inﬂammatory disorder and can also be
termed IgG4-related dacryoadenitis and sialadenitis. Disease
activity indices are needed in the assessment of chronic
diseases. Glucocorticoid treatment is now uniformly per-
formed for MD, but the disease is known to be likely to
relapse with reductions in steroid dose. In our data (SMART:International Journal of Rheumatology 3
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Date of visit Pt’s name
Not swell at al Still swell a little
Swell as the same
as ﬁrst visit
Swell more since
ﬁrst visit 
Not dry at al Still dry a little
Dry as the same
as ﬁrst visit
Dry more
since ﬁrst visit 
25/ 7 / 2010 
Please tell us your conditions at today. 
Please check  in the applicable box.
Not swell at al Still swell a little
Swell as the same
as ﬁrst visit
Swell more since
ﬁrst visit 
Not dry at al Still dry a little
Dry as the same
as ﬁrst visit
Dry more
since ﬁrst visit 
Glucocorticoid dose at the last visit
Scores of A + C/B + D
3/1 points
15 mg/day
Mikulicz’s disease activity questionnaire  
(A) How do you like the swelling of upper eyelids in comparison with ﬁrst visit?  
(B) How do you like dry eyes in comparison with ﬁrst visit?
(C) How do you like the swelling of parotid and submandibular
      portion in comparison with ﬁrst visit?
(D) How do you like dry mouth in comparison with ﬁrst visit?
Figure 1: The English version of the Mikulicz’s disease activity questionnaire (MAQ). An example of a completed MAQ as used in the clinic
during routine visits by patients.
Table 1: Characteristics of analyzed patients with Mikulicz’s disease.
(1) Persistent (>3 months), symmetrical swelling of the lacrimal, parotid, and submandibular glands, involving at least two pairs.
(2) Serologically high levels of immunoglobulin (lg)G4 (≥13.5mg/L).
(3) Marked lgG4-positive plasmacyte inﬁltration (≥50% lgG4-positive/lgG-positive cells in ﬁve high power ﬁelds) into lacrimal and
salivary gland tissues.
In terms of diagnosis, lgG4-related Mikulicz’s disease is deﬁned as satisfying item 1 and either item 2 and/or item 3. This form of systemic lgG4-related disease
often accompanies multiple organ lesions. Sarcoidosis, Castleman’s disease, Wegener’s granulomatosis, and malignant lymphoma need to be considered as
diﬀerential diagnoses.4 International Journal of Rheumatology
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Figure 2: Serial changes in MAQ scores and serum IgG4 levels in patients who started treatment during the observation period. (a) MAQ
scores decreased rapidly after starting treatment. Some patients showed initial sicca symptoms, and scores rose when the steroid dose was
reduced to 8–10mg/day. (b) Serum IgG4 levels decreased after initiation of treatment. Some patients showed reelevation of IgG4 levels prior
to MAQ scores at <15mg/day of PSL. Virtually no cases showed any elevation of serum IgG4 at the dosage of 5mg/day.
Sapporo Medical University and related institutes database
for investigation and best treatments of IgG4-related dis-
ease), patients withdrawn from steroid presented with mild
symptoms (data not shown). We may thus be able to
select the dose of glucocorticoid or nonsteroidal treatment,
including biologic agents, depending on disease activity
during therapy for MD. Recurrence of MD is currently often
diagnosed based on physical and imaging ﬁndings. On the
other hand, risk factors for relapse remain unclear, and no
studies have reported analyses of ﬂare-up signs in MD. We
therefore developed the MAQ as a clinical evaluation scoring
system for MD and analyzed the clinical application of this
questionnaire.
The lacrimal and salivary glands are involved in MD.
Our database revealed that the chief complaints in most
patients are glandular enlargement and impaired secretion.
Other complaints, including pain, are rarely observed. We
therefore asked patients to assess swelling and dryness in
the lacrimal and salivary glands. The degrees of subjective
symptoms were set at four levels compared to the ﬁrst visit:
disappearance of symptoms, slight improvement, no change,
or progression. This was in consideration of patients, to
avoid them wondering which option they should check. This
approach to assessment was well received by patients and did
not interfere with practice.
As expected, results showed high MAQ scores before
treatment and decreased scores after glucocorticoid admin-
istration. Many patients showed improvements of more than
5 points, with improvements in both swelling and dryness.
We have previously described the eﬃcacy of glucocorticoids
in short-term treatment [3]. This analysis demonstrated
that the MAQ accurately reﬂects such results. However,
some patients still presented with sicca symptoms after
undergoing steroid treatment. MD is not considered prone
to destruction of the glands [7], but progressive ﬁbrosis
can irreversibly reduce glandular function. Diﬀerent factors
can also aﬀect sicca symptoms, including mental condition,
diabetesmellitus,andconcomitantmedications.Ideally,each
individual factor should be assessed in terms of impacts
on dryness, but this is obviously impractical to achieve.
The MAQ is expected to adequately evaluate the changing
condition of the same patients if no other factors change.
With respect to relapse, the elevation of dryness scores
preceded that of swelling scores in most cases. The origin of
glandularenlargementinMDremainsunclear,butglandular
impairment may occur before swelling in MD. The present
analysis did not include any missed cases with recurrence.
MAQ scores appeared to accurately reﬂect relapses in MD.
However, two patients presented with relapse in other
organs despite MAQ scores of 0. One case exhibited relapse
from MD alone to bronchitis, and another showed relapse
from MD with IgG4-related tubulointerstitial nephritis to
retroperitoneal ﬁbrosis alone. In the other cases of ﬂare-up,
ﬁve patients presented with the involvement of other organs.
In all, new lesions in other organs at the time of relapse
were revealed in 7 of the 11 cases. This result oﬀers a good
reminder that MD is a systemic disease. To address this issue,
developing indices for each organ and then combining them
is one option, but development of an integrated assessment
may be a better approach. The activity index for IgG4-RD
requires one such integrated assessment.
The present analysis also examined the association be-
tween MAQ scores and serum level of IgG4. Levels of serum
IgG4 elevated 3 to 6 months before clinical identiﬁcation
of recurrence. MAQ scores tended to increase later than
levels of serum IgG4. Cases presenting with other organ
involvementsdespiteanMAQscoreof0alsoshowedelevated
serum IgG4 levels. Tabata pointed out the possibility that
concentrations of serum IgG4 reﬂect IgG4-RD disease activ-
ity [8]. Fluctuations in serum IgG4 levels would thus also
be important in assessing the disease activity of IgG4-RD.
Comparing degrees of elevation of serum IgG4 in ﬂare-upsInternational Journal of Rheumatology 5
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Figure 3: Serial changes in MAQ scores and serum IgG4 levels in patients with relapse (R). (a) Serial changes in MAQ scores. In many cases,
MAQ scores had gradually elevated 1 to 6 months before relapse. ∗ and # in the bar graphs denote the same cases. Case ∗ showed two ﬂares,
while case # experienced relapse three times. (b) Serial changes in serum IgG4 levels which had elevated several months before relapse.6 International Journal of Rheumatology
Analyzed cases
(DEC2009-AUG2011)
18
Newly treated cases
7
Registered cases
72
Ongoing followup cases
41
Transfered or
dropped out cases 
31
Already treated or
no ﬂare-up cases
23
Relapsed cases
11
Male 3 : Female 4   Male 7 : Female 4  
Complications:
AIP 1, RF 2, prostatitis 1 
Recurrence pattern:
MD + Lung 2, only BR 1
AIP: autoimmune pancreatitis, RF: retroperitoneal ﬁbrosis, MD: Mikulicz’s disease,
TIN: tubulointerstitial nephritis, BR: bronchitis
Only MD−→MD + TIN + RF 1, MD + RF 1,
MD + AIP−→MD 1, MD + AIP 1
MD + RF−→MD + RF 2
MD + TIN−→ only RF 1
MD + AIP + RF−→MD + TIN + RF 1
Figure 4: Diagnostic criteria for IgG4-related MD (as proposed by the Japanese Society for Sj¨ ogren’s syndrome in 2008).
among patients is diﬃcult, given thewidevariations between
individual cases. We therefore did not examine correlations
between the degree of IgG4 elevation and changes in MAQ
score in the present study.
Clinical research in the present study was designed to
maximize the number of cases within a limited period, but
this study remains ongoing. As a result, we are hopeful that
we will encounter novel ﬁndings using the integrated data
over the longer term. We would like to perform a multicenter
study and ascertain the utility of MAQ scores on a large scale
in the future. The MAQ appears to oﬀer a useful assessment
of disease activity in MD and may help to catalyze the
development of a disease activity index for IgG4-RD.
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